BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23722880)

  • 41. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
    Mudd SR; Holich KD; Voorbach MJ; Cole TB; Reuter DR; Tapang P; Bukofzer G; Chakravartty A; Donawho CK; Palma JP; Fox GB; Day M; Luo Y
    Mol Imaging Biol; 2012 Oct; 14(5):617-24. PubMed ID: 22167582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
    McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
    PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
    Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [
    Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
    Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake.
    Schwartz JL; Tamura Y; Jordan R; Grierson JR; Krohn KA
    Nucl Med Biol; 2004 May; 31(4):419-23. PubMed ID: 15093811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arginine deiminase, a potential anti-tumor drug.
    Ni Y; Schwaneberg U; Sun ZH
    Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 3'-[
    Li C; Zhang X; Pang L; Huang Y; Gao Y; Sun X; Yu J; Meng X
    Mol Imaging Biol; 2019 Aug; 21(4):713-721. PubMed ID: 30406513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
    Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
    J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
    Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
    Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
    Rex K; Lewis XZ; Gobalakrishnan S; Glaus C; Silva MD; Radinsky R; Burgess TL; Gambhir SS; Coxon A
    Nucl Med Biol; 2013 May; 40(4):458-63. PubMed ID: 23454250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
    Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
    Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
    Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.